Phase II and KEYNOTE B-61: Comparative Analysis of Cancer Trials

Medical experts compare the updated results of a Phase II trial and KEYNOTE B-61, both presented at ASCO 2024, giving a comprehensive overview of these pivotal studies.

EP: 1.Overview of RCC Histology and Incidence Rates

EP: 2.CLEAR Trial Updates From ASCO 2024

EP: 3.TKIs, Disease Progression and Subsequent Therapy in RCC

EP: 4.ASCO 2024 Updates: nccRCC + Chromophobe RCC

EP: 5.PAPMET Phase II Trial Advances Cancer Treatment Landscape

EP: 6.Chromophobe Renal Cell Carcinoma: Key Features and Diagnosis

EP: 7.Examining Predictors of Chromophobe Renal Cell Carcinoma Recurrence

EP: 8.ASCO 2024: Abstract 4512 Overview

EP: 9.Key Takeaways in Renal Cell Carcinoma from Abstract 4512

Now Viewing

EP: 10.Phase II and KEYNOTE B-61: Comparative Analysis of Cancer Trials

Recent Videos